No. 18

Neuroblastoma: decision on malignancy already made during pregnancy

In neuroblastomas, cell division gets out of hand: instead of dividing chromosomes (blue) evenly among daughter cells, several spindle poles (green) and spindle apparatuses (red) form, even leading to the breakage of chromosomes or their incorrect division.
In neuroblastomas, cell division gets out of hand: instead of dividing chromosomes (blue) evenly among daughter cells, several spindle poles (green) and spindle apparatuses (red) form, even leading to the breakage of chromosomes or their incorrect division.

Neuroblastomas, common tumors in infants and young children, develop during the first trimester of pregnancy, regardless of their later clinical course. It is already at this time that it is decided whether they will later regress spontaneously or progress aggressively. This has now been discovered by a team of researchers from the German Cancer Research Center (DKFZ) and the Hopp Children's Cancer Center Heidelberg (KiTZ). Based on the development history of the cancer cells, it is also possible to make predictions about the course of the disease, the study shows using a mathematical model. This should help in the future to make the right therapy decision for affected children.

The Hopp Children's Cancer Center Heidelberg (KiTZ) is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD) and the University of Heidelberg (Uni HD).

Neuroblastomas are among the most common tumors in infants and young children. They occur in the area of the adrenal glands or along the spine in the neck, chest or abdomen. A distinctive feature of neuroblastomas is their extremely variable disease course: In some cases, the tumor regresses completely without any therapy. In about half of the patients, however, even highly intensive therapy cannot prevent aggressive growth.

However, there is currently no internationally recognized uniform method to reliably distinguish high-risk patients from those with a favorable disease course already at initial diagnosis.

“Until now, it was assumed that these were completely different neuroblastoma diseases,“ says Thomas Höfer of the German Cancer Research Center (DKFZ). The team led by research group leaders Höfer and Frank Westermann from the Hopp Children's Cancer Center Heidelberg (KiTZ) and DKFZ has now been able to show for the first time that both neuroblastomas from high-risk patients and those with a favorable disease course have a common cellular origin. Already in embryonic development during the first third of pregnancy, cell division starts to get out of control and already there the course is set for a favorable or aggressive course in children, the present study shows.

For this purpose, the scientists decoded the tumor genome of 100 patients with neuroblastomas of different stages. They then reconstructed the genesis of the tumors on the basis of specific genetic alterations. “It is assumed that genetic changes in our genome accumulate randomly and over time at a constant rate like sand in an hourglass,“ explains the study's first author Verena Körber from Thomas Höfer's Theoretical Systems Biology group at DKFZ. “This is also called a molecular clock and can be measured. With the help of a specially developed mathematical model, we were able to reconstruct a family tree of neuroblastoma development from this,“ Körber continues.

The family tree shows at what point the cancer cells take very different developmental paths and which genetic events are decisive for this. By correlating the results with the clinical course, the scientists were able to divide neuroblastomas into two categories: Those in which genetic alterations lead to tumor growth early on. “Paradoxically, these are the tumors with a favorable course, even if they initially grow faster. But drastic genetic events no longer take place, giving the cancer cells the tools to become immortal in the long term,“ explains Frank Westermann, an expert in childhood neuroblastoma at KiTZ and DKFZ. “They are also usually detected earlier in children because of their early rapid growth.“

The second category is neuroblastomas that become malignant later but then grow aggressively. They undergo a more complex and protracted evolution. Thomas Höfer sees the reasons for this in the fact that, due to the cell environment or internal genetic damage, most of these neuroblastoma cells die: “Due to this selection pressure, however, they then develop particularly aggressive mechanisms to permanently escape cell death and remain infinitely active in division. Until that happens, however, the tumors remain small for the time being and are therefore unfortunately diagnosed later.“

Mathematical models of cancer evolution are also currently being researched in adult oncology in order to predict the course of disease in leukemias, for example.
In children with neuroblastoma, they could help distinguish young high-risk patients from children who don't need therapy at all, the research team hopes. “We are currently working to establish tumor evolution as a reliable biomarker in neuroblastoma,“ Westermann says. “Ideally, such an analysis would then take only about three weeks after sample collection to provide an individualized therapy recommendation.“

An image for this press release is available for download at:
https://www.kitz-heidelberg.de/fileadmin/media/kitz/news/2023/230327-mitose_test-KiTZ.jpg 

Caption:
In neuroblastomas, cell division gets out of hand: instead of dividing chromosomes (blue) evenly among daughter cells, several spindle poles (green) and spindle apparatuses (red) form, even leading to the breakage of chromosomes or their incorrect division.

Original publication:
Körber, V. et al. Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome. In: Nature Genetics (Online publication March 27, 2023)
DOI: 10.1038/s41588-023-01332-y

Note on use of images related to press releases
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: “Source: Sina Kreth/KiTZ“.
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ's Press Office (phone: ++49-(0)6221 42 2854, E-mail: presse@dkfz.de). Any commercial use is prohibited.

About DKFZ

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

Form

Form data is loaded ...